Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study)

Background: Epilepsy is one of the most common symptoms of brain tumors. It is often drug resistant and generally worsen patients' quality of life (QoL). Brain tumors release glutamate among other mediators, contributing to seizures onset, and this is accompanied by an increased AMPA receptors&...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Neurol
Egile Nagusiak: Coppola, Antonietta, Zarabla, Alessia, Maialetti, Andrea, Villani, Veronica, Koudriavtseva, Tatiana, Russo, Emilio, Nozzolillo, Agostino, Sueri, Chiara, Belcastro, Vincenzo, Balestrini, Simona, Ferlazzo, Edoardo, Giannarelli, Diana, Bilo, Leonilda, Maschio, Marta
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Neurology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7336340/
https://ncbi.nlm.nih.gov/pubmed/32695064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00592
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak